Chief Executive Officer and Director
Dr. Wrighton-Smith is our Chief Executive Officer and a Director. He has held both positions since founding Oxford Immunotec in 2002. Before founding Oxford Immunotec, Dr. Wrighton-Smith held senior positions with PowderJect Pharmaceuticals PLC, as director of strategic development, and managing director of PowderJect Diagnostics Ltd., a subsidiary of PowderJect engaged in the development of cellular immune-based diagnostics. He earned his master’s degree in Engineering, Economics and Management, and his doctorate in Medical Engineering from Oxford University.
Chief Financial Officer
Mr. McLaughlin is our Chief Financial Officer, a position he has held since joining our company in April 2019. Before joining Oxford Immunotec, Mr. McLaughlin spent over 18 years at General Electric, working for their Healthcare, Aviation, Corporate and Lighting business divisions. Mr. McLaughlin was the Chief Financial Officer for GE Healthcare in N. America from 2017 through April 2019. Prior to that he was in GE Aviation from 2009 through 2016 where he was an Executive, Financial Planning & Analysis, leading the team responsible for FP&A and Investor Relations and preparing financial and investor relations reports for the Aviation division, followed by 2 years as the CFO of the Avionics division and finishing his time in Aviation as the CFO of the global supply chain. Earlier in his career, Mr. McLaughlin spent 6 years on the GE Corporate Audit Staff and was ultimately responsible for the global audit coverage of GE Aviation, Transportation and Water. Mr. McLaughlin earned his Bachelor’s degree of Science in Business Administration from Northeastern University.
General Counsel and Company Secretary
Ms. Kidd is our General Counsel and Company Secretary, a position she has held since joining our company in November 2019. Before joining Oxford Immunotec, Ms. Kidd served at Aegerion Pharmaceuticals for 3 years. From 2018 to 2019 as Deputy General Counsel and from 2016 to 2018 as VP, Legal EMEA , where she oversaw all legal and compliance activities in EMEA. Prior to that Ms. Kidd was a Director, Business Conduct EMEA at Gilead Sciences and held senior in-house legal roles at Baxter Healthcare from 2010 to 2015. From 2007 to 2010 Ms. Kidd worked at Covington & Burlington LLP advising life science clients on corporate and commercial transactions, with special expertise on global collaborations and cross-border deals. Before her career in law, Ms. Kidd spent nearly 15 years as a research and development scientist. Ms. Kidd earned her Bachelor’s degree in Chemistry from the University of Hertfordshire.